NURO™

How NURO™ PTNM therapy works for bladder control.

Request Appointment All Services

How NURO™ PTNM therapy works

For bladder control

If you’re ready to try an advanced treatment for bladder control and want to start with a nonsurgical option, neuromodulation with the NURO™ device may be an option.

Regain bladder control in a few weeks

Therapy delivered by the NURO™ system targets the miscommunication that occurs between the brain and bladder.²-⁴ Here are some facts about the device:

The most common side effects of percutaneous tibial neuromodulation (PTNM) are temporary and include mild pain or skin inflammation at or near the stimulation site.

  • Does not require surgery
  • Used to treat the symptoms of overactive bladder
  • Delivered during 30-minute sessions once per week for 12 weeks
  • May require follow-up visits for therapeutic maintenance
  • Does not cause unpleasant side effects like oral medications can¹

How the NURO™ PTNM system works

Treatment with the NURO™ system involves a series of 30-minute office appointments:

Evidence suggests that bladder control problems may be caused by miscommunication between the bladder and the brain.²-⁴ The tibial nerve connects to nerves responsible for bladder function.

  • Your provider will gently place shallow acupuncture-like needle near the tibial nerve near the ankle.
  • Mild electrical pulses from the device are sent through the needle, targeting the nerve to help you regain control of your bladder. It doesn’t hurt, but you may feel tingling.
  • The doctor removes the needle before you leave.
NURO percutaneous tibial neuromodulation system

Clinical evidence for PTNM therapy

For bladder control

Clinical studies show that Medtronic bladder control therapy by the NURO™ system is an effective treatment for people with overactive bladder (OAB).⁵,⁶ Highlights from these studies include the following results:

  • Nearly 4 out of 5 patients saw their urinary urge incontinence episodes cut in half after 12 weeks.*⁵
  • Approximately 70% reduction in episodes of incontinence per day after completing the first 12 weekly sessions.⁵
  • 40% of OAB patients became fully continent.⁵
  • Significant improvement in health-related quality of life.†,⁵-⁷
  • Improvements trended as patients completed more sessions and they had the best results when finishing all 12 sessions.⁷

What if NURO™ PTNM therapy doesn’t work for me?

If the therapy doesn’t work how you hoped, speak to your doctor about the InterStim™ neuromodulation system.

Request an Appointment

Tell us how to reach you, and our office will follow up to confirm scheduling. Please do not include sensitive medical details, SSN, insurance ID numbers, medication lists, or full medical history in this form.

This form is for appointment requests only and should not be used for emergencies.

Phone: (208) 356-0004

Email: scheduling@mountainwesturology.com

You do not need to put personal health details here. Please do not include symptoms, medications, SSN, insurance IDs, or detailed medical history.

Please review

Important Safety Information

Medtronic NURO™ Percutaneous Tibial Neuromodulation (PTNM) treats overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.

PTNM is not intended for patients with pacemakers or implantable defibrillators, patients prone to excessive bleeding, patients with nerve damage that could impact either percutaneous tibial nerve or pelvic floor function, or on patients who are pregnant or planning pregnancy. Do not use if the skin in the area of use is compromised.

Exercise caution for patients with heart problems. Adverse events are typically temporary, and include mild pain, minor inflammation and bleeding near treatment site.

This therapy is not for everyone. Please consult your physician to decide whether PTNM is right for you. A prescription is required. For further information, please call Medtronic at 800-328-0810.

USA Rx Only Rev 0915.

* Evaluated using the Patient Perception of Bladder Condition (PPBC) scale.

† Evaluated using the Overactive Bladder Symptom Quality of Life Questionnaire (OAB-q).

References

  1. Visco A, Brubaker L, Richter HE et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. New Engl J Med. 2012;367(19):1803-1813.
  2. Dasgupta R, Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral neuromodulation for urinary retention. J Urol. 2005;174:2268-2272.
  3. Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862-1867.
  4. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466-474.
  5. Kobashi K, Nitti V, Margolis E, et al. A prospective study to evaluate efficacy using the NURO percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. J Urol. 2019;131:77-82.
  6. Kobashi K, Margolis E, Sand P, et al. Prospective study to evaluate quality of life with percutaneous tibial neuromodulation in drug-naïve patients with overactive bladder syndrome. Presented at the 2018 Annual Meeting of the International Continence Society.
  7. Kobashi K, Sand P, Margolis E, et al. Increasing therapy effect over twelve weeks with the NURO™ percutaneous tibial neuromodulation system in drug naïve patients with overactive bladder syndrome (OAB). Presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2019 Winter Meeting. Neurourology and Urodynamics. 2019;38(S1), S79.

Manufacturer Information

Medtronic NURO™ therapy information

Medtronic NURO™ indications, safety, and warnings